» Articles » PMID: 26786550

Clinical Characteristics and Outcomes of HIV-associated Immune Complex Kidney Disease

Abstract

Background: The pathogenesis and natural history of HIV-associated immune complex kidney disease (HIVICK) is not well understood. Key questions remain unanswered, including the role of HIV infection and replication in disease development and the efficacy of antiretroviral therapy (ART) in the prevention and treatment of disease.

Methods: In this multicentre study, we describe the renal pathology of HIVICK and compare the clinical characteristics of patients with HIVICK with those with IgA nephropathy and HIV-associated nephropathy (HIVAN). Poisson regression models were used to identify risk factors for each of these pathologies.

Results: Between 1998 and 2012, 65 patients were diagnosed with HIVICK, 27 with IgA nephropathy and 70 with HIVAN. Black ethnicity and HIV RNA were associated with HIVICK, receipt of ART with IgA nephropathy and black ethnicity and CD4 cell count with HIVAN. HIVICK was associated with lower rates of progression to end-stage kidney disease compared with HIVAN and IgA nephropathy (P < 0.0001). Patients with HIVICK who initiated ART and achieved suppression of HIV RNA experienced improvements in estimated glomerular filtration rate and proteinuria.

Conclusions: These findings suggest a pathogenic role for HIV replication in the development of HIVICK and that ART may improve kidney function in patients who have detectable HIV RNA at the time of HIVICK diagnosis. Our data also suggest that IgA nephropathy should be viewed as a separate entity and not included in the HIVICK spectrum.

Citing Articles

From Diagnosis to Dialysis: Managing Primary Membranous Nephropathy in a Patient Living With Human Immunodeficiency Virus (HIV).

Opare-Addo K, Atencah S, Dadzie S, Solomon A Cureus. 2024; 16(8):e68036.

PMID: 39347143 PMC: 11433521. DOI: 10.7759/cureus.68036.


Prevalence and predictors of long-term progression of chronic kidney disease in people with HIV in Ghana from 2003-2018.

Chadwick D, Barker F, Smith C, Perditer O, Hardy Y, Owusu D BMC Nephrol. 2024; 25(1):241.

PMID: 39075393 PMC: 11288112. DOI: 10.1186/s12882-024-03537-7.


The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment Paradigm of CKD in Africa: An African Association of Nephrology Panel Position Paper.

Jarraya F, Niang A, Bagha H, Tannor E, Sumaili E, Wan D Kidney Int Rep. 2024; 9(3):526-548.

PMID: 38481515 PMC: 10928012. DOI: 10.1016/j.ekir.2023.12.019.


Autoimmunity and Infection in Glomerular Disease.

Casuscelli C, Longhitano E, Maressa V, Di Carlo S, Peritore L, Di Lorenzo S Microorganisms. 2023; 11(9).

PMID: 37764071 PMC: 10538233. DOI: 10.3390/microorganisms11092227.


Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: A case report.

Wang J, Sun Y, Kang Z, Zhang S, Yu C, Zhang W World J Clin Cases. 2023; 11(22):5309-5315.

PMID: 37621578 PMC: 10445080. DOI: 10.12998/wjcc.v11.i22.5309.